Status:
COMPLETED
SSEP Fluctuations Due to Dexmedetomidine During Posterior Spine Fusion
Lead Sponsor:
George Papanicolaou Hospital
Conditions:
Spinal Fusion
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Intravenous anesthetic agents as far as inhaled agents produce a dose depended increase in latency and decrease in amplitude of SomatoSensory Evoked Potential (SSEP). Dexmetedomidine, a highly selecti...
Detailed Description
Patients 18-75 years old, ASA (physical status classification system) I-III, scheduled for elective posterior spinal fusion surgery were enrolled in this prospective study. After induction in anesthes...
Eligibility Criteria
Inclusion
- Patients with ASA physical status 1-3
Exclusion
- Patients with ASA physical status \>3,
- Body Mass Index (BMI) over 30,
- indication for rapid sequence induction,
- any contraindication for receiving b-blocker,
- Glasgow Coma Scale (GCS) \<13,
- history of drug abuse,
- neurologic deficit or preoperatively foreseen delayed extubation,
- preoperative heart rate\<45.
Key Trial Info
Start Date :
March 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT03236727
Start Date
March 1 2014
End Date
June 1 2016
Last Update
August 3 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.